Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells

BACKGROUND: Breast cancer (BC) cells secrete soluble factors that accelerate osteoclast (OC) differentiation, leading to the formation of osteolytic bone metastases. In the BOLERO-2 trial, BC patients with bone involvement who received Everolimus had a delayed tumor progression in the skeleton as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Simone, Valeria, Ciavarella, Sabino, Brunetti, Oronzo, Savonarola, Annalisa, Cives, Mauro, Tucci, Marco, Opinto, Giuseppina, Maiorano, Eugenio, Silvestris, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606500/
https://www.ncbi.nlm.nih.gov/pubmed/26468083
http://dx.doi.org/10.1186/s12885-015-1717-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606500/
https://www.ncbi.nlm.nih.gov/pubmed/26468083
http://dx.doi.org/10.1186/s12885-015-1717-8

Ejemplares similares